Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.


Clinical Abstracts from Overseas: September 2007

July 8th 2010

Articles in this issue include: 1) England: GAMEC for Untreated or Relapsed Refractory Germ-Cell Tumors Preventing Oxaliplatin-Induced Peripheral Neuropathy 2) Australia: Immunodeficiency May Be Linked to Multiple Cancer Types 3) Sweden: Long-Term Steroid Use in Rheumatoid Arthritis Has One Benefit, at Least 4) Netherlands: Increasing Survival of Infants With Acute Lymphoblastic Leukemia, and more

Five-year Follow-Up of 300 Patients Treated with Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy of CLL

July 8th 2010

Final results for the complete cohort of 300 patients with chronic lymphocytic leukemia (CLL) receiving the FCR (fludarabine, cyclophosphamide, and rituximab)regimen were presented at this year%u2019s American Society of Clinical Oncology meeting.

Active Symptom Control With or Without Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

July 8th 2010

Chemotherapy is widely used in the treatment of malignant mesothelioma, but it has never been compared in a randomized trial with active symptom control (ASC) alone.

"Longboat" Delivery May Invade Tumor Cells and Deliver Chemotherapy

July 8th 2010

Like the Vikings of old, scientists are hoping a new "longboat" drug delivery system will compromise the walls of resistant cancer cells and fight them with high-dose chemotherapy released only when they are inside.

Children's Eyes May Be Spared by New Intra-arterial 'Chemosurgery'

July 8th 2010

An experimental intra-arterial delivery system injects high-dose chemotherapy directly into the ocular tumor and may not only save the eye, but the vision as well.

Patient Recruitment Completed for First Phase III Clinical Trial of GVAX Immunotherapy for Prostate Cancer

July 8th 2010

Cell Genesys has announced that it has completed recruitment of more than 600 patients into VITAL-1, the first of two ongoing Phase III clinical trials of GVAX immunotherapy for prostate cancer.

NCCN Updates Guidelines for Kidney and Cervical Cancer

July 8th 2010

The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 21 leading cancer centers worldwide, develops and publishes clinical practice guidelines to promote the importance of continuous quality improvement. The primary goal of all its initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The Academy: July/August 2007

July 8th 2010

The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing farther in pursuit of knowledge and new discoveries. In this issue we highlight presentations from the 43rd annual ASCO meeting as well as research being done at Massachusetts General Hospital and Dana-Farber Cancer Institute in Boston and the University of Texas Southwestern Medical Center in Dallas.

Physicians' Financial News for July/August 2007

July 8th 2010

Physicians' Financial News focuses on newsworthy and/or notable companies in the oncology/biotech sector. In this issue: 1) GlaxoSmithKline 2) Ventana Medical Systems Inc. and Roche Holding AG, and more

Clinical Abstracts From Overseas: July 7, 2010

July 7th 2010

Among the articles provided in this issue are topics presented at the 43rd annual meeting of the American Society of Clinical Oncology.

Clinical Trial Reports: July/August 2007

July 7th 2010

Among the Clinical Trials reported in this issue are: PHASE III: 1) More Positive News in GPC Biotech's Trial With Satraplatin 2) Sanofi-Aventis Presents Positive Results in Three Oncology Programs 3) Imatinib (Gleevec) After GIST Surgery Achieves Significant Survival Benefit, and more

Reimbursement and Managed Care News: July/August 2007

July 7th 2010

In this issue we highlight topics presented at the 43rd annual meeting of the American Society of Clinical Oncology: 1) Focus Groups and Advisory Boards: To What Extent Do They Supplement Oncologists' Income? 2) The High Overhead Cost of Complying With National Guidelines, and more

Swiss Approve Brain Cancer Vaccine

July 7th 2010

According to the U.S. National Cancer Institute, there are 19,000 new cases of primary brain cancer diagnosed each year. The five-year survival rate is around 30%. Brain cancers can strike all ages, and are the leading cause of cancer deaths in children under the age of 20.

Reporting from ASCO

July 7th 2010

At ASCO's 43rd annual meeting in Chicago, more than 4,000 abstracts were presented, and 25,000 specialists from around the world convened to hear the latest advances in cancer treatment.

The Extended ASCO Coverage Issue

July 7th 2010

This issue of Oncology & Biotech News presents some of the most noteworthy and newsworthy information from the 43rd annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

An Editorial Board of Your Peers

July 6th 2010

In keeping with our goal of reporting on the practical aspects of oncology, in this issue we highlight the new National Comprehensive Cancer Network%u2019s (NCCN) updated clinical practice guidelines for kidney and cervical cancers.

Flash Findings: Cancer Facts: July 6, 2010

July 6th 2010

A collection of cancer statistics and facts

Bio-Buzz: Advances in the Treatment of Multiple Myeloma

July 6th 2010

Treatment advances focus on the potential use of Bortezomib and Lenalidomide in the front-line setting to improve patients' response rates.

The RapidReporter: Recent Developments, Findings, and Research in Head and Neck Cancer

July 6th 2010

Identifying head and neck cancer patients who possess the FcyR genotype may help predict whether they will respond to monoclonal antibodies, which work by killing cancer cells bearing epidermal growth factor receptors (EGFR) on their surface.

Reimbursement and Managed Care News for October 207

June 30th 2010

Topics covered in this issue include: 1) Bad News for Health Plans: MRIs Gain in Breast Cancer Detection 2) Do Terminally Ill Patients Have a Right to Receive Unproven Drugs? 3) Benefits of HPV Vaccine Still Unclear, but Time Will Tell 4) Updated Kidney Cancer Guidelines Focus on Medication Revisions and more